![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CT45A10 |
Gene summary for CT45A10 |
![]() |
Gene information | Species | Human | Gene symbol | CT45A10 | Gene ID | 102723631 |
Gene name | cancer/testis antigen family 45 member A10 | |
Gene Alias | CT45-5 | |
Cytomap | Xq26.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P0DMU8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
102723631 | CT45A10 | HCC1_Meng | Human | Liver | HCC | 3.87e-30 | 1.24e-01 | 0.0246 |
102723631 | CT45A10 | HCC2 | Human | Liver | HCC | 2.11e-13 | 3.14e+00 | 0.5341 |
102723631 | CT45A10 | S014 | Human | Liver | HCC | 1.32e-22 | 5.00e-01 | 0.2254 |
102723631 | CT45A10 | S015 | Human | Liver | HCC | 4.75e-05 | 1.81e-01 | 0.2375 |
102723631 | CT45A10 | S016 | Human | Liver | HCC | 2.40e-09 | 2.30e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CT45A10 | SNV | Missense_Mutation | c.394N>G | p.Lys132Glu | p.K132E | P0DMU9 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-BI-A20A-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CT45A10 | SNV | Missense_Mutation | c.179N>A | p.Thr60Lys | p.T60K | P0DMU9 | protein_coding | tolerated(0.26) | benign(0.037) | TCGA-FU-A3NI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
CT45A10 | SNV | Missense_Mutation | c.416N>A | p.Arg139Gln | p.R139Q | P0DMU9 | protein_coding | tolerated(0.27) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CT45A10 | SNV | Missense_Mutation | novel | c.299N>T | p.Ser100Ile | p.S100I | P0DMU9 | protein_coding | tolerated(0.37) | probably_damaging(0.991) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CT45A10 | SNV | Missense_Mutation | novel | c.501N>T | p.Lys167Asn | p.K167N | P0DMU9 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CT45A10 | SNV | Missense_Mutation | novel | c.202N>A | p.Gln68Lys | p.Q68K | P0DMU9 | protein_coding | tolerated(0.33) | probably_damaging(0.932) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CT45A10 | SNV | Missense_Mutation | c.313G>T | p.Asp105Tyr | p.D105Y | P0DMU9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CT45A10 | SNV | Missense_Mutation | c.278N>A | p.Pro93His | p.P93H | P0DMU9 | protein_coding | tolerated(0.5) | possibly_damaging(0.634) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD | |
CT45A10 | SNV | Missense_Mutation | novel | c.429N>C | p.Lys143Asn | p.K143N | P0DMU9 | protein_coding | deleterious(0) | benign(0.113) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CT45A10 | SNV | Missense_Mutation | novel | c.407N>A | p.Cys136Tyr | p.C136Y | P0DMU9 | protein_coding | tolerated(0.09) | benign(0.001) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |